New hope for brain cancer: drug combo aims to extend survival
NCT ID NCT04922723
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug daratumumab to standard chemotherapy and radiation can help people with a newly diagnosed aggressive brain cancer called glioblastoma. About 16 participants will receive the combination treatment. The goal is to see if the new approach improves survival without causing severe side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West Virginia University Cancer Institute Mary Babb Randolph Cancer Center
Morgantown, West Virginia, 26506, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?